While the major Western guidelines recommend adjuvant chemotherapy for patients having Stage II colorectal cancer (CRC) with 'high-risk' features, e.g., pT4 and lymphovascular involvement, the survival benefit has not been confirmed. To understand the actual clinical practice for this patient subgroup in Japan, we performed a questionnaire survey of specialist institutions regarding two topics: institutional policy of adjuvant chemotherapy, and the percentage of patients receiving adjuvant chemotherapy among 'high-risk' Stage II CRC patients. Among the 55 responders out of 60 institutions (response rate, 91.7%), 80.0% did not routinely administer adjuvant chemotherapy for 'high-risk' Stage II patients. The median percentage of 'high-risk' Stage II patients receiving adjuvant chemotherapy was 25%, with ≤30% in 35 institutions, and >60% in 12. In summary, performance of adjuvant chemotherapy for patients with 'high-risk' Stage II CRC varied substantially, even among these specialist institutions, and a majority of patients received no adjuvant chemotherapy.
Introduction
With the rapid aging of society and improvement of diagnostics, colorectal cancer (CRC) has surged to the position of most common cancer in Japan; the expected new cases and deaths amounted to 149 500 and 53 000 in 2017, respectively (1) . Approximately one-third of the surgically resected CRCs were categorized as pathological Stage II (T3-4N0) disease (2). Improving the treatment outcome of this major patient subgroup would have great clinical impact.
Although surgical resection is the principal treatment for early CRC, postoperative adjuvant chemotherapy often plays an important role in the improvement of survival. Adjuvant chemotherapy is the internationally accepted standard of care with established efficacy for Stage III colon cancer, but its usefulness for Stage II disease has not been proven and remains controversial.
While two old meta-analyses had shown a survival benefit of adjuvant chemotherapy using 5-FU agents alone for Stage II disease, other pooled analyses and a large population database review have concluded otherwise (3) . Moreover, clinical outcomes of Stage II CRC patients reported recently in Japan were rather favorable; i.e., the recurrence rate was~13% (4, 5) . Based on these findings, we conclude that a broad international consensus has not been formed as to whether adjuvant chemotherapy should be administered to all patients with Stage II colon cancer (6) (7) (8) .
On the other hand, since the mid-2000s, the major Western clinical guidelines (6-8) list T4 lesions, less than 12 examined lymphnodes (LNs), bowel perforation and obstruction, lymphovascular involvement, poorly-differentiated histology, perineural invasion and elevated CEA as poor prognostic factors in Stage II colon cancer and recommend adjuvant chemotherapy for Stage II colon cancer patients with these 'high-risk' features. However, the recommendation of using these 'high-risk' factors in treatment decision is not based on scientific evidence obtained in prospective studies, and the benefit of adjuvant chemotherapy in 'high-risk' Stage II patients has not been confirmed. Therefore, it is current clinical practice in Japan that each physician determines the necessity of postoperative adjuvant chemotherapy on their own accord in this setting.
In this study, we therefore carried out questionnaire surveys to understand the recent status of the treatment strategy for 'high-risk' Stage II CRC patients in specialist institutions in Japan.
Methods
The questionnaires were performed in November 2016 (Q1) and March 2018 (Q2 and Q3). The questionnaires were sent by e-mail to the member institutions of the Colorectal Cancer Study Group of Japan Clinical Oncology Group (JCOG), a group of leading specialist institutions of CRC treatment in Japan.
Q1: Which factors are considered when selecting candidate for adjuvant chemotherapy in Stage II CRC patients in your institute? (multiple answers allowed)
Answer choice: T factor, histological type, amount of fibrous stroma, invasive growth pattern, lymphovascular invasion, perineural invasion, tumor budding, pre-operative CEA, bowel obstruction, perforation, number of examined lymph node, others.
Q2: What is the basic institutional policy of administering postoperative adjuvant chemotherapy in Stage II colorectal cancer patients with 'high-risk' features?
Answer choices: 1) We administer adjuvant chemotherapy routinely for all candidates.
2) We do NOT administer adjuvant chemotherapy routinely for all candidates, and indication of adjuvant chemotherapy is determined based on physician's rating of risk for recurrence and attitude of each patient.
3) We do not administer adjuvant chemotherapy regardless of whether patients have 'high-risk' features or not.
Q3: What percentage of Stage II patients with 'high-risk' features actually received adjuvant chemotherapy in your institute in 2017?
The survey was based on the premise that the patient is received curative surgery without prior chemotherapy and/or radiotherapy and is enough fit to receive adjuvant chemotherapy safely, i.e., favorable PS, acceptable age in principal <80 years, and no sever comorbidities. In Q2 and Q3, the definition of 'high-risk' features was not provided, because this survey aimed to investigate actual status of clinical practice in the JCOG institutions, in which original institutional criteria for 'high-risk' of recurrence were assumed to be adopted. Each institute provided one response for each question. The responses to the questionnaire were collected by e-mail or fax.
Results
Among the 60 institutions that participated in the study group, 44 responded to Q1 (response rate, 73.3%), and 55 responded to Q2 and Q3 (response rate, 91.7%).
Q1: Factors considered in selecting candidate for adjuvant chemotherapy in Stage II CRC Among 44 responders, the following factors were lined-up as factors considered in selecting candidate for adjuvant chemotherapy in Stage II CRC. The numbers of responses were shown in parentheses: perforation (33), pT factor (27), lymphovascular involvement (26), histology (25), bowel obstruction (18), number of LN retrieved (14), perineural invasion (10), tumor budding (7) and the others (5).
Q2: Basic institutional policy of postoperative adjuvant chemotherapy in 'high-risk' Stage II CRC patients
Postoperative adjuvant chemotherapy was adopted as a routine clinical practice for Stage II patients with 'high-risk' features in only three institutions (5.5% of responders) (Fig. 1) . On the contrary, adjuvant chemotherapy was not administered in principle in this situation in eight institutions (14.5% of responders). The remaining 44 institutions (80.0% of responders) replied that they administered adjuvant chemotherapy for such candidates on a case-by-case basis, but not routinely.
Q3: Proportion of 'high-risk' Stage II patients receiving adjuvant chemotherapy
The percentage of 'high-risk' Stage II patients who received adjuvant chemotherapy varied substantially among the institutes, ranging from 0% to 90% (Fig. 2) . The median and mean of the institutional figures were 25.0% and 32.2%, respectively. More specifically, the number of institutions at which adjuvant chemotherapy was administered for 0-10% of the candidates was 20 (36.4% of responders), and this treatment was performed in <30% of the candidates in 35 institutions (63.6% of responders). On the other hand, in 12 institutions (21.8% of responders), more than 60% candidates received adjuvant chemotherapy postoperatively.
Discussion
The Colorectal Cancer Study Group of JCOG consists of a total of 60 high-volume specialist hospitals for CRC treatment across Japan. The results of our simple questionnaire survey revealed that the indications for adjuvant chemotherapy in 'high-risk' Stage II CRC varied substantially, even among the JCOG member institutions, and a majority of 'high-risk' Stage II patients received follow-up care without adjuvant chemotherapy after curative resection. Such current status of clinical practice in Japan could be different from the type of approach for 'high-risk' Stage II colorectal cancer patients recommended in the Western guidelines (6) (7) (8) .
One possible reason for the gap between Japan and the West may be the uncertainty of these risk factors; e.g., the impact on prognosis differs substantially among the factors. In the SACURA trial (4), a randomized controlled trial exclusively focused on Stage II colon cancer in which prognostic benefit of 1-year tegafur-uracil (UFT) administration over surgery-alone was investigated, the hazard ratios for RFS of 'high-risk' factors such as pT4, lymphatic invasion, and poorly-differentiated histology were 2.53 (95% confidence interval [CI], 1.96-3.25), 1.06 (95% CI, 0.84-1.35), and 0.65 (95% CI, 0.33-1.25), respectively. It follows that prognosis of patients differs according to the type and number of risk factors they have. Moreover, recently, new histopathological parameters, e.g., tumor budding and fibrotic cancer stroma type, have been demonstrated as promising risk factors (9, 10) . Considering the low proportion of patients receiving adjuvant chemotherapy in our survey, Japanese physicians might narrow the candidate down to patients with strong or multiple risk factors. In clinical practice in Japan, a majority of physicians may strongly consider a risk-benefit balance of adjuvant chemotherapy for individual Stage II CRC patients.
Second, there is no robust evidence as to whether the Stage II CRC patients with 'high-risk' features benefit from adjuvant chemotherapy. Subgroup analysis in the SACURA trial demonstrated no definite trend toward favorable RFS in the group of 'high-risk' patients with adjuvant UFT (4). Recently, prognostic prediction power of new biomarkers, including gene panels such as Oncotype DX (11), was reported in curatively resected CRC. However, there are no data based on sufficient scientific evidence regarding the efficacy of these biomarkers with which the value of adjuvant chemotherapy would be improved by selecting appropriate candidate patients for it. Although the prognostic prediction is certainly becoming more precise, we are still partway through identifying the population of Stage II CRC patients who would benefit from adjuvant chemotherapy.
The limitation of our survey was that it was carried out in one study group consisted of 60 high-volume hospitals. However, a survey previously conducted by the Japanese Society for Cancer of the Colon and Rectum (JSCCR) with the data of 46 304 patients treated in 96 institutions over Japan revealed similar population of Stage II patients receiving adjuvant chemotherapy; 28.6% in 2001, 24.0% in 2005, and 22.0% in 2010 (12) . And no considerable disparity in the prognosis of Stage II patients exist among the nationwide cancer registry (2), the CRC registry of JSCCR (13), the SACURA trial (4), and the JCOG randomized studies (unpublished subgroup analysis data); the 5-year relapse free survival rates were 85-87%, and the 5-year overall survival rates were~95%. Based on these findings, we considered that the results of our survey could be comparable to clinical practice in Japan.
In summary, our questionnaire survey disclosed considerable variation among treatment strategies in the field of adjuvant chemotherapy for Stage II CRC patients in Japan. We believe the results highlight the importance of resolving the long-standing clinical question, 'Who benefits from adjuvant chemotherapy?' All efforts to launch a large-scale prospective multicenter study of good quality are urgently needed, in which evidence-based treatment decision factors in Stage II CRC -not only risk factors for recurrence, but also those associated with the benefit of adjuvant chemotherapy -will be determined.
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